(Q38219430)

31 August 2017

title

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013). (English)

1 reference

31 August 2017

0 references

Raghava R Kethiri

1

1 reference

31 August 2017

Rajagopal Bakthavatchalam

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

11 June 2014

1 reference

Expert Opinion on Therapeutic Patents

31 August 2017

published in

1 reference

31 August 2017

volume

24

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

745-757

1 reference

Pathophysiology, pleiotrophy and paradigm shifts: genetic lessons from Parkinson's disease

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

A review of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Parkinson's disease: clinical features and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Diagnosis and treatment of Parkinson disease: molecules to medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

LRRK2 signaling pathways: the key to unlocking neurodegeneration?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

The genetics of Parkinson's syndromes: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Recent advances in the genetics of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Localization of LRRK2 to membranous and vesicular structures in mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Biochemical and pathological characterization of Lrrk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

LRRK2 and human disease: a complicated question or a question of complexes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

LRRK2 in Parkinson's disease: protein domains and functional insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Kinase activity of mutant LRRK2 mediates neuronal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Role of LRRK2 kinase dysfunction in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

LRRK2 in Parkinson's disease: biochemical functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Kinases as targets for Parkinson's disease: from genetics to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Manganese-induced dopaminergic neurodegeneration: insights into mechanisms and genetics shared with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Novel cinnoline-based inhibitors of LRRK2 kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

LRRK2 mutations in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.907275

10.1517/13543776.2014.907275

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference